Healthcare [ 12/13 ] | Biotechnology [ 116/164 ]
NASDAQ | Common Stock
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.
Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases.
BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 2, 24 | -0.20 Increased by +78.26% | -0.71 Increased by +71.83% |
| Feb 22, 24 | -0.96 Decreased by -4.35% | -0.91 Decreased by -5.49% |
| Nov 2, 23 | -1.08 Decreased by -16.13% | -0.82 Decreased by -31.71% |
| Aug 3, 23 | -0.98 Decreased by -1.30 K% | -0.83 Decreased by -18.07% |
| May 4, 23 | -0.92 Increased by +22.69% | -0.83 Decreased by -10.84% |
| Feb 23, 23 | -0.92 Increased by +8.91% | -0.85 Decreased by -8.24% |
| Nov 3, 22 | -0.93 Increased by +12.26% | -0.99 Increased by +6.06% |
| Aug 4, 22 | -0.07 Increased by +89.39% | -0.63 Increased by +88.89% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 211.12 M Increased by +11.46 K% | -35.22 M Increased by +80.09% | Decreased by -16.68% Increased by +99.83% |
| Dec 31, 23 | 1.75 M Decreased by -6.68% | -168.15 M Decreased by -7.81% | Decreased by -9.64 K% Decreased by -15.53% |
| Sep 30, 23 | 4.09 M Increased by +1.11 K% | -177.00 M Decreased by -19.26% | Decreased by -4.33 K% Increased by +90.15% |
| Jun 30, 23 | 1.64 M Decreased by -97.77% | -157.90 M Decreased by -365.98% | Decreased by -9.62 K% Decreased by -12.05 K% |
| Mar 31, 23 | 1.83 M Increased by +7.79% | -176.85 M Increased by +28.32% | Decreased by -9.68 K% Increased by +33.50% |
| Dec 31, 22 | 1.87 M Decreased by -85.49% | -155.97 M Decreased by -5.98% | Decreased by -8.34 K% Decreased by -630.27% |
| Sep 30, 22 | 338.00 K Decreased by -85.58% | -148.42 M Increased by +4.82% | Decreased by -43.91 K% Decreased by -560.05% |
| Jun 30, 22 | 73.75 M Increased by +36.51% | 59.37 M Increased by +161.62% | Increased by +80.50% Increased by +145.14% |